目的:评价联合肝动脉切除（HAR）治疗肝门部胆管癌手术的安全性和有效性。方法:检索Pubmed、The Cochrane Library、Embase、Web of Science、中国知网、万方数据资源系统、维普-中文科技期刊系统数据库和中国生物医学文献数据库等数据库，收集联合HAR与未联合HAR治疗肝门部胆管癌安全性和有效性分析的相关随机对照研究或回顾性研究。检索时限为2006年1月1日至2019年12月31日。采用Review Manager 5.3软件对提取的数据指标进行荟萃分析。结果:共收集到文献14篇，总计2 374例肝门部胆管癌患者被纳入研究。荟萃分析结果显示，HAR组围手术期死亡率高于对照组（n OR= 1.70， 95%n CI= 0.02~2.90， n P=0.05），术后总并发症发生率高于对照组（n OR= 1.28， 95%n CI= 0.93~1.76， n P=0.13），两者与对照组相比差异均无统计学意义。亚组分析显示两组肝功能衰竭（n OR= 1.15， 95%n CI= 0.73~1.82， n P=0.54）、胆瘘（n OR= 1.20， 95%n CI= 0.78~1.84， n P=0.40）、腹腔感染发生率（n OR= 0.98， 95%n CI= 0.53~1.83， n P=0.95）差异无统计学意义。HAR组的R0切除率高于对照组，其差异也无统计学意义（n OR= 1.08， 95%n CI= 0.66~1.75， n P=0.77）。HAR组淋巴结转移率高于对照组（n OR= 2.48， 95%n CI= 1.05~5.84， n P=0.04），1年（n OR=0.48， 95%n CI= 0.32~0.72， n P=0.000 5）、3年（n OR=0.51， 95%n CI= 0.36~0.72， n P=0.000 1）和5年（n OR=0.50， 95%n CI= 0.35~0.70， n P<0.000 1）生存率低于对照组。术后给予联合化疗药物治疗的HAR 组患者生存率明显提高（n OR= 7.33， n P=0.02）。n 结论:联合HAR治疗肝门部胆管癌安全性可以接受，但术后生存差，可能与联合HAR的肝门部胆管癌患者淋巴结转移率高有关，因此开展该术式仍需谨慎。若术后联合辅助化疗可能提高生存期。“,”Objective:To evaluate the safety and effectiveness of combined hepatic artery resection for the treatment of hilar cholangiocarcinoma.Methods:We searched Pubmed, The Cochrane Library, Embase, Web of Science, China Knowledge Network, Wanfang Data Resource System, Vip-Chinese Sci-tech Journal System Database, and China Biomedical Literature Database, and collected the randomized controlled studies or retrospective studies on the safety and efficacy of combined hepatic artery resection and non-hepatic artery resection in the treatment of hilar cholangiocarcinoma. The search period is from January 1, 2006 to December 31, 2019. Review Manager 5.3 software was used to analyze the extracted data indicators.Results:A total of 14 articles were collected, and a total of 2 374 patients with hilar cholangiocarcinoma were included in the study. Meta-analysis results showed that the perioperative mortality in the hepatic artery resection (HAR) group was higher than that of the control group (n OR=1.70, 95%n CI=0.02-2.90, n P=0.05), and the total postoperative morbidity rate was higher than that of the control group (n OR=1.28, 95%n CI= 0.93-1.76, n P=0.13), both of which were not statistically significant compared with the control group. Subgroup analysis showed that the incidence of liver failure (n OR=1.15, 95%n CI= 0.73-1.82, n P=0.54), biliary fistula (n OR=1.20, 95%n CI= 0.78-1.84, n P=0.40), and abdominal infection in the two groups (n OR=0.98, 95%n CI= 0.53-1.83, n P=0.95) was without significant difference. The R0 resection rate of the HAR group was higher than that of the control group, and the difference was not statistically significant (n OR=1.08, 95%n CI=0.66-1.75, n P=0.77). The rates of lymph node metastasis in the HAR group were higher than that in the control group (n OR= 2.48, 95%n CI= 1.05-5.84, n P=0.04). One-year(n OR=0.48, 95%n CI= 0.32-0.72, n P=0.000 5), 3-year (n OR= 0.51, 95%n CI=0.36-0.72, n P=0.000 1), and 5-year (n OR=0.50, 95%n CI=0.35-0.70, n P<0.000 1) survival rates of HAR group were lower than those of the control group. The survival rates of patients in HAR group treated with combined chemotherapy drugs after operation were significantly improved (n OR= 7.33, n P=0.02).n Conclusions:The safety of combined HAR treatment for hilar cholangiocarcinoma is acceptable, but poor postoperative survival may be related to the high lymph node metastasis rate. Therefore, it is still necessary to be cautious in carrying out this operation. Combined with adjuvant chemotherapy after surgery may improve survival.